In this article, we will take a look at the 10 Stocks That Could 10X Over the Next 10 Years.

The last few years have been incredible for stock investors, with the S&P 500 returning 86% between 2023 and 2025. However, valuations have progressively increased over the past three years, and the sustainability of corporate earnings may be of concern in 2026.

Following the latest stock market decline, the S&P 500 is now trading at approximately 20.6 times aggregate forward earnings estimates. That’s still substantially over its long-term average of mid- to high teens, but significantly lower than the 22x earnings multiple it traded at at the beginning of the year.

Meanwhile, consumer confidence in the US is declining. According to a new University of Michigan survey, consumer mood fell across age groups, political parties, and income levels in March. The survey portrays an ominous state of how Americans are contending with the economic consequences of the Iran conflict.

That said, Mike Wilson, Morgan Stanley’s chief US equity strategist, says the market decline is “as significant” as those in 2015 and 2023. Simultaneously, earnings growth is predicted to rise to 17% over the next 12 months. According to Wilson’s study, when these two patterns aligned in previous years, the S&P 500 gained a median 10% over the following six months, exceeding the long-term average of 5%.

With that, let’s look at the 10 stocks that could 10x over the next 10 years.

Our Methodology

To compile a list of stocks that could 10x over the next 10 years, we used multiple financial websites, including EBC Financial, Nasdaq, Yahoo Finance, and Motley Fool. These stocks hold the potential to be tenbaggers, and are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Rigetti Computing Inc. (NASDAQ:RGTI)

Rigetti Computing Inc. (NASDAQ:RGTI) ranks among the stocks that could 10x over the next 10 years. Following Rigetti Computing Inc. (NASDAQ:RGTI)’s fourth-quarter fiscal 2025 results, Rosenblatt reiterated a Buy rating and a $40 price target for the company’s shares on March 5. The company’s EPS of -$0.03 was in line with analyst expectations, but revenue totaled $1.9 million, considerably lower than the expected $2.32 million.

The company stated that it had rectified the fidelity issue on the Cepheus-1-108Q machine and intends to ship it at the ideal 99.5% by the end of March. Rosenblatt stated that the comparatively swift resolution of the technical issue highlights the advantages of Rigetti having its own fabrication facility.

Meanwhile, Needham maintained a Buy rating on Rigetti Computing Inc. (NASDAQ:RGTI) while lowering its stock price target from $51 to $31, citing sector compression. In addition, the firm raised Rigetti’s fiscal 2026 revenue estimate from $18.5 million to $21.0 million, citing increasing system sales as a driving force.

Rigetti Computing Inc. (NASDAQ:RGTI) is a quantum computing and semiconductor hardware company that designs and builds superconducting quantum processors. Through its cloud-based platform, the company provides quantum-computing-as-a-service to commercial, academic, and government partners.

9. Ferrari NV (NYSE:RACE)

Ferrari NV (NYSE:RACE) ranks among the stocks that could 10x over the next 10 years. Evercore ISI reaffirmed its Outperform rating and $475.0 price target for Ferrari NV (NYSE:RACE) on March 19. The firm stated that Ferrari will most likely lower its projections for the first half of 2026 and offer further information on how the Middle East war may affect 2026 earnings if it lingers into the second half of the year.

According to Evercore ISI, Ferrari NV (NYSE:RACE) typically builds enough support to outperform its initial revenue expectations by about 5%, though the firm added that Ferrari NV (NYSE:RACE) rarely raises expectations on the first-quarter call.

If the war is prolonged, the possibility of slower sales in the Middle East could increase, which might limit any near-term upside to 2026 figures. However, the firm believes there is little risk of negative adjustments in the near term and that this will demonstrate the adaptability that Ferrari’s global supply model allows during disputes.

Ferrari NV (NYSE:RACE), more commonly known as Ferrari, is an Italy-based manufacturer, designer, and retailer of luxury sports cars. It also produces one-off and limited-series cars and operates under the Ferrari brand.

8. Rivian Automotive, Inc. (NASDAQ:RIVN)

Rivian Automotive, Inc. (NASDAQ:RIVN) ranks among the stocks that could 10x over the next 10 years. Following the announcement of a cooperation with Uber Technologies Inc., Stifel reaffirmed its Buy rating and $20 price target for Rivian Automotive, Inc. (NASDAQ:RIVN) on March 19. The partnership will result in the deployment of as many as 50,000 fully autonomous R2 vehicles, with a starter rollout of about 10,000 vehicles starting in 2028 and the option to buy up to 40,000 more R2s beginning in 2030.

The company plans to roll out thousands of unmanned R2 robotaxis in around 25 cities across the US, Canada, and Europe around 2031. In that vein, Uber intends to invest up to $1.25 billion, with around $300 million already allocated.

According to analyst Stephen Gengaro, the collaboration offers “a meaningful positive for Rivian’s autonomous capabilities and the expansion of its R2 platform.”

Rivian Automotive, Inc. (NASDAQ:RIVN) designs, develops, and manufactures category-defining electric vehicles and accessories. Its operations are divided into the following segments: Automotive, Software, and Services.

7. Joby Aviation Inc. (NYSE:JOBY)

Joby Aviation Inc. (NYSE:JOBY) ranks among the stocks that could 10x over the next 10 years. Canaccord Genuity reaffirmed its Hold rating and $15.50 price target for Joby Aviation Inc. (NYSE:JOBY) on March 12, following the company’s disclosure of a major accomplishment in its aircraft testing program. Joby Aviation Inc. (NYSE:JOBY) stated that its first conforming aircraft for Type Inspection Authorization testing conducted its first test flight in Marina, California.

The company anticipates that this aircraft and five other planes in assembly will commence TIA testing with FAA pilots for credit later in 2026. Joby Aviation Inc. (NYSE:JOBY) corporate pilots will conduct ground and flying exams before FAA pilots.

Canaccord sees the impending TIA flight tests, conclusion of the Means of Compliance for the S4 eVTOL, and beginning of eIPP flight tests in the latter half of 2026 as key investor triggers for the company this year.

Joby Aviation Inc. (NYSE:JOBY) is an air mobility company that researches, develops, tests, manufactures, and sells electric vertical takeoff and landing aircraft in the US, Japan, Europe, and internationally.

6. CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) to $110 from $105 on March 17, retaining an Overweight rating in response to the company’s convertible note issuance. CRISPR Therapeutics AG (NASDAQ:CRSP) raised $600 million in convertible notes due in March 2031, convertible at $76.56 per share and with an effective interest rate of 1.73%. The company also allowed initial purchasers to pick up an extra $50 million in notes, with the transaction set to finalize in March of this year.

Moreover, CRISPR Therapeutics AG (NASDAQ:CRSP) plans to disclose Phase I data on zugo-cel in autoimmune diseases and B-cell lymphoma in the latter half of 2026. The company also plans to begin Phase I research on CTX340 in the first half of 2026 and CTX460 in mid-2026.

Meanwhile, in the second half of 2026, CRISPR Therapeutics AG (NASDAQ:CRSP) will provide Phase Ib data on CTX310 and proof-of-concept Phase II data on CTX611 in patients undergoing total knee replacement.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology, using its proprietary gene sequencing platform to develop precise treatments for diseases requiring DNA modification.

Click to continue reading and see the 5 Stocks That Could 10X Over the Next 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.